Multiple Myeloma
Conditions
Keywords
Carfilzomib, Lenalidomide, Dexamethasone, 15-326
Brief summary
The purpose of this study is to test whether giving high doses of carfilzomib along with the other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by patients. In addition, the study is designed to test the amount of remaining myeloma cells in the body after treatment with higher carfilzomib doses which is known as minimal residual disease (MRD).
Interventions
DRUGCarfilzomib
DRUGLenalidomide
DRUGDexamethasone
Sponsors
Onyx/Amgen
Celgene
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed patients with histologically confirmed MM based on the following criteria: * Clonal plasma cells in the bone marrow * Measurable disease within the past 4 weeks defined by any one of the following: * Serum monoclonal protein ≥ 1.0 g/dL * Urine monoclonal protein \>200 mg/24 hour * Involved serum immunoglobulin free light chain \> 10 mg/dL AND abnormal kappa/lambda ratio * Evidence of underlying end organ damage and/or myeloma defining event attributed to underlying plasma cell proliferative disorder meeting at least one of the following: * Hypercalcemia: serum calcium \>0.25 mmol/L (\> 1 mg/dL) above upper limit of normal or ≥ 2.75 mmol/L (11 mg/dL) * Anemia: hemoglobin value \<10 g/dL or \> 2 g/dL below lower limit of normal * Bone disease: ≥ 1 lytic lesions on skeletal X-ray, CT, or PET-CT. For patients with 1 lytic lesion, bone marrow should demonstrate ≥10% clonal plasma cells * Clonal bone marrow plasma cell percentage ≥60% * Involved/un-involved serum free light chain ratio ≥100 and involved free light chain \>100 mg/L. * 1 focal lesion on magnetic resonance imaging study (lesion must be \>5 mm) in size * Creatinine Clearance ≥ 60 ml/min. CrCl can be measured or estimated using Cockcroft-Gault method * Age ≥ 18 years at the time of signing the informed consent documentation * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Absolute neutrophil count (ANC) ≥ 1.0 K/uL, hemoglobin ≥ 8 g/dL, and platelet count ≥ 75 K/uL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator. Transfusions and growth factors are permissible. * Adequate hepatic function, with bilirubin \< 1.5 x the ULN, and AST and ALT \< 3.0 x ULN. * All study participants must be able to tolerate one of the following thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin (coumadin) or alternative anti-coagulant. * All study participants must be registered into the mandatory eREMS® program, and be willing and able to comply with the requirements of REMS®. * Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. * A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
Exclusion criteria
* Patients receiving \>1 cycle of prior treatment or concurrent systemic treatment for multiple myeloma. * Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted * Bisphosphonates are permitted * Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted * Prior treatment with radiotherapy is permitted * Prior treatment for smoldering myeloma is permitted with a washout period of 4 weeks from last dose. Smoldering patients previously treated with carfilzomib are excluded. * Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 4 weeks from last dose (on a trial or outside a trial) are eligible * Plasma cell leukemia * POEMS syndrome * Amyloidosis * Pregnant or lactating females. Because there is a potential risk for adverse events nursing infants secondary to treatment of the mother with carfilzomib in combination with lenalidomide. These potential risks may also apply to other agents used in this study. * Uncontrolled hypertension or diabetes * Active hepatitis B or C infection * Known or suspected HIV or serologically positive * Has significant cardiovascular disease with NYHA Class III or IV symptoms, EF\<40% or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within 6 months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination. Echocardiogram will be performed during screening evaluation. * Moderate or severe pulmonary hypertension defined as PASP \> 50mm Hg. For those patients were PASP is indeterminate, moderate to severe symptoms of pulmonary hypertension (World Health Organization functional assessment class III or IV) will be used to determine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Dose Limiting Toxicity | Cycle 1, up to 28 days | To find the maximum tolerated dose.A DLT is defined as any of the below toxicities with attribution to one or more of the study drugs that occur during Cycle 1. All AEs should be considered relevant to determining dose-limiting toxicities and to reporting unless the event can clearly be determined to be UNRELATED to the drug. NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1: Carfilzomib 45mg/m2/Dose * Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.
* Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
* Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days
* Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23
* Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23
Carfilzomib
Lenalidomide
Dexamethasone | 3 |
| Dose Level 2: Carfilzomib 56mg/m2/Dose * Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.
* Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
* Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days
* Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23
* Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23
Carfilzomib
Lenalidomide
Dexamethasone | 3 |
| MTD: Carfilzomib * Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.
* Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
* Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days
* Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23
* Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23
Carfilzomib
Lenalidomide
Dexamethasone | 23 |
| Total | 29 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 4 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 3 |
Baseline characteristics
| Characteristic | Dose Level 1: Carfilzomib 45mg/m2/Dose | Total | MTD: Carfilzomib | Dose Level 2: Carfilzomib 56mg/m2/Dose |
|---|---|---|---|---|
| Age, Continuous | 63 years | 61 years | 60 years | 68 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 2 Participants | 2 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 27 Participants | 21 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 4 Participants | 3 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 4 Participants | 4 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 21 Participants | 16 Participants | 3 Participants |
| Region of Enrollment United States | 3 Participants | 29 Participants | 23 Participants | 3 Participants |
| Sex: Female, Male Female | 2 Participants | 14 Participants | 10 Participants | 2 Participants |
| Sex: Female, Male Male | 1 Participants | 15 Participants | 13 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 4 / 23 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 23 / 23 |
| serious Total, serious adverse events | 0 / 3 | 1 / 3 | 15 / 23 |
Outcome results
Primary
Number of Patients With Dose Limiting Toxicity
To find the maximum tolerated dose.A DLT is defined as any of the below toxicities with attribution to one or more of the study drugs that occur during Cycle 1. All AEs should be considered relevant to determining dose-limiting toxicities and to reporting unless the event can clearly be determined to be UNRELATED to the drug. NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.
Time frame: Cycle 1, up to 28 days
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dose Level 1: Carfilzomib 45mg/m2/Dose | Number of Patients With Dose Limiting Toxicity | Number of participants with DLT | 0 Participants |
| Dose Level 1: Carfilzomib 45mg/m2/Dose | Number of Patients With Dose Limiting Toxicity | Number of participants without DLT | 3 Participants |
| Dose Level 2: Carfilzomib 56mg/m2/Dose | Number of Patients With Dose Limiting Toxicity | Number of participants with DLT | 0 Participants |
| Dose Level 2: Carfilzomib 56mg/m2/Dose | Number of Patients With Dose Limiting Toxicity | Number of participants without DLT | 3 Participants |
| MTD: Carfilzomib | Number of Patients With Dose Limiting Toxicity | Number of participants with DLT | 0 Participants |
| MTD: Carfilzomib | Number of Patients With Dose Limiting Toxicity | Number of participants without DLT | 23 Participants |